the use of azacitidine in hr-mds and the potential of combination therapies
Published 8 months ago • 122 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
4:44
establishing the clinical benchmark of azacitidine in patients with mds
-
1:37
a phase i/ii trial of seclidemstat in combination with azacitidine for patients with mds and cmml
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:50
magrolimab azacitidine in untreated higher-risk mds
-
1:17
the curative potential of allosct in the treatment of hr-mds
-
3:17
venetoclax with azacitidine in hr-mds
-
5:52
venetoclax in combination with azacitidine for patients with treatment-naïve hr-mds
-
3:03
venetoclax and 5-azacytidine for the treatment of mds and cmml
-
21:38
drawing the line: the rationale behind blood tube collection order
-
8:04
electronic journal of medical science (jms) | rsud dr. zainoel abidin
-
1:32:42
mds & covid-19 vaccine
-
1:31
pevaz update: pevonedistat & azacitidine in r/r mds and mds/mpn after dnmti failure
-
2:43
novel therapies in the future of mds treatment
-
5:36
venetoclax and azacitidine in mds patients
-
2:00
optimizing hma treatment in hr-mds: azacitidine versus decitabine
-
1:48
azacitidine and venetoclax maintenance post allosct in high-risk t-all
-
0:44
mds: an update on pevonedistat plus azacitidine
-
1:41
novel therapies for high-risk mds
-
2:04
state-of-the-art treatment for hr-mds
-
1:35
phase i study of plx51107, a novel bet inhibitor, in combination with azacitidine in r/r mds and aml
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
3:01
the role of piez01 variants in patients with mds